These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 29562192)

  • 1. Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape.
    Wellenstein MD; de Visser KE
    Immunity; 2018 Mar; 48(3):399-416. PubMed ID: 29562192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy.
    Lian X; Yang K; Li R; Li M; Zuo J; Zheng B; Wang W; Wang P; Zhou S
    Mol Cancer; 2022 Jan; 21(1):27. PubMed ID: 35062950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunometabolism at the Nexus of Cancer Therapeutic Efficacy and Resistance.
    Traba J; Sack MN; Waldmann TA; Anton OM
    Front Immunol; 2021; 12():657293. PubMed ID: 34079545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors?
    Puré E; Lo A
    Cancer Immunol Res; 2016 Apr; 4(4):269-78. PubMed ID: 27036971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Immune Cell Lineage Reprogramming in Cancer.
    Leavenworth JW; Shi LZ; Wang X; Wei H
    Front Immunol; 2021; 12():838464. PubMed ID: 35126385
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy-induced microenvironmental changes in cancer.
    Ma Y; Yang H; Pitt JM; Kroemer G; Zitvogel L
    J Mol Med (Berl); 2016 May; 94(5):497-508. PubMed ID: 26931513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteoglycans and Immunobiology of Cancer-Therapeutic Implications.
    Tzanakakis G; Neagu M; Tsatsakis A; Nikitovic D
    Front Immunol; 2019; 10():875. PubMed ID: 31068944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Regulation and Antitumor Effect of TIM-1.
    Du P; Xiong R; Li X; Jiang J
    J Immunol Res; 2016; 2016():8605134. PubMed ID: 27413764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
    Cui Y; Guo G
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy.
    Meng MB; Wang HH; Cui YL; Wu ZQ; Shi YY; Zaorsky NG; Deng L; Yuan ZY; Lu Y; Wang P
    Oncotarget; 2016 Aug; 7(35):57391-57413. PubMed ID: 27429198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Expanding World of N-MYC-Driven Tumors.
    Rickman DS; Schulte JH; Eilers M
    Cancer Discov; 2018 Feb; 8(2):150-163. PubMed ID: 29358508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune Response.
    Reiser J; Banerjee A
    J Immunol Res; 2016; 2016():8941260. PubMed ID: 27314056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changing mutational and adaptive landscapes and the genesis of cancer.
    Liggett LA; DeGregori J
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):84-94. PubMed ID: 28167050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-related interleukins: old validated targets for new anti-cancer drug development.
    Setrerrahmane S; Xu H
    Mol Cancer; 2017 Sep; 16(1):153. PubMed ID: 28927416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of fatty acid metabolism in tumourigenesis: Beyond providing nutrition (Review).
    Yu XH; Ren XH; Liang XH; Tang YL
    Mol Med Rep; 2018 Dec; 18(6):5307-5316. PubMed ID: 30365095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy.
    Andrews MC; Reuben A; Gopalakrishnan V; Wargo JA
    Front Immunol; 2018; 9():946. PubMed ID: 29780391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-based identification of cancer patients at high risk of progression.
    Vano YA; Petitprez F; Giraldo NA; Fridman WH; Sautès-Fridman C
    Curr Opin Immunol; 2018 Apr; 51():97-102. PubMed ID: 29554496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fundamental role of mechanical properties in the progression of cancer disease and inflammation.
    Mierke CT
    Rep Prog Phys; 2014 Jul; 77(7):076602. PubMed ID: 25006689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA Deregulation in Cancer Cells and the Tumor Microenvironment.
    Rupaimoole R; Calin GA; Lopez-Berestein G; Sood AK
    Cancer Discov; 2016 Mar; 6(3):235-46. PubMed ID: 26865249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.